Roquette and Qualicaps combine to expand global footprint

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags roquette qualicaps Excipients Manufacturing Supply chain acquisition

Pharma and plant-based ingredient giant, Roquette, has confirmed its acquisition of Qualicaps from the Mitsubishu Chemical Group.

Qualicaps manufactures hard capsules and pharmaceutical-related equipment and is the third-largest producer for oral dosage solutions.

The company is a ‘renowned global player, relying on high-quality products and a strong innovation pipeline’. It has a workforce of 1,400 employees located in different sites in Asia, Europe, and the Americas.

Roquette is a family-owned global leader in plant-based ingredients and a leading provider of pharmaceutical excipients. The company currently operates in more than 100 countries, has a turnover of around €5 billion and, with this acquisition, will employ around 10,000 people worldwide.

Expanding Roquette’s global footprint in the pharma business

This strategic investment offers Roquette the ability to expand the global footprint of its pharmaceutical business, as well as enrich its offerings of oral dosage solutions. Roquette’s deep knowledge and expertise in the development of pharmaceutical excipients will be further enhanced by Qualicaps’ expertise in capsules, as well as by their assets and infrastructure.

Roquette said that with the acquisition it aims to consolidate its leadership position while serving customers, and the market, with ‘superior solutions and an expanded choice’.

Hard and soft capsules, filler and binders, disintegrants among other solutions will be on offer through the combined business.

Qualicaps is an ideal addition to Roquette thanks to its shared commitment to innovation, quality and excellence. Its global footprint, with manufacturing and R&D sites in Japan, Spain, Romania, Canada, the USA, and Brazil, will allow Roquette to expand its presence and be closer to its customers and markets.

Pharmaceutical solutions

Pierre Courduroux, CEO of Roquette, said: “This acquisition is a key milestone in our journey to reinforce our global leadership in pharmaceutical solutions and to consolidate our position in nutrition and health markets.

“Thanks to our combined workforce, we will continue to grow our business through collaboration with our customers and bring our expertise and innovation to all stages of pharmaceutical development.”

He said that together, Roquette and Qualicaps will continue to offer high-quality, highly regarded products and services and provide technical capabilities through a single point of contact for its expanded offering.

The combined companies believe this will provide customers with an improved level of service and access to a stronger technical base for the development of future solutions and innovations.

Advancing healthcare solutions worldwide

Seiichiro Matsumura, CEO of Qualicaps, said: “Today marks a pivotal moment in Qualicaps' journey. Partnering with Roquette, a renowned global leader in pharmaceutical excipients, marks the beginning of a transformative era of growth and innovation for our company.

“Together, we are poised to lead innovation, enrich our product portfolio, and deliver greater value to our global customer and stakeholder base. This partnership is an important step forward in our commitment to advancing healthcare solutions worldwide.”

Roquette was founded in 1933 and from raw materials of natural origin, its goal is to enable a whole new plant protein cuisine as well as offer pharmaceutical solutions that play a key role in medical treatments. It develops ingredients for food, nutrition, and health markets.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us